319 results
8-K
EX-99.2
LEXX
Lexaria Bioscience Corp
16 Feb 24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:30pm
provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness
8-K
EX-99.1
LEXX
Lexaria Bioscience Corp
16 Feb 24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:30pm
and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility
8-K
EX-1.1
cgu 68b4solf02j8td
16 Feb 24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:30pm
8-K
EX-10.1
enikrm241w2m2b45by
16 Feb 24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:30pm
424B5
t6lzq c6i
16 Feb 24
Prospectus supplement for primary offering
6:01am
8-K
EX-99.1
oops6pbi
24 Jan 24
Regulation FD Disclosure
2:12pm
S-8
EX-4.1
l45892um
18 Jan 24
Registration of securities for employees
2:38pm
8-K
EX-99.1
yzprw7xb ippq4wergaz
4 Jan 24
Lexaria’s Patented Technology Improved the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide
5:07pm
8-K
EX-99
yhd15k9
16 Oct 23
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
1:13pm
8-K
EX-99.1
5rx vuavq4
12 Oct 23
Lexaria Granted Two New Patents in Canada
3:57pm
8-K
EX-1.1
yinmzjlzv2l2
3 Oct 23
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-10.1
fvl60ycll 97
3 Oct 23
Entry into a Material Definitive Agreement
4:05pm
424B5
mkdp7v
2 Oct 23
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
rbypvsz ysgy64lb
28 Jul 23
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
12:11pm
8-K
EX-99.1
jw6m8d9zk9jzfmrsiooy
10 May 23
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
5:16pm